Response of tic and obsessive-compulsive symptoms to striosomal dopaminergic modulation in tic-related OCD: an open-label pilot study

Objectives This study investigated the therapeutic potential of striosomes in addressing ICSDs, focusing on the treatment response of tic and obsessive-compulsive (OC) symptoms in tic-related OCD (T-OCD) to a pharmacological intervention designed to enhance striosomal dopamine signaling through D1-type receptors (D1Rs). Methods Ten participants with T-OCD [30% male; mean age, 40.5 years (SD 20.1); mean age at onset, 9.2 years (SD 4.1)] received L-DOPA/carbidopa (50 mg) plus chlorpromazine-phenolphthalinate (5 mg), with doses increased stepwise to three times daily over 8 weeks, then maintained for 1 year. We used the Yale Global Tic Severity Scale (YGTSS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) for clinical assessments. For statistical analyses, we used repeated-measures ANOVA with Dunnett’s post hoc tests and calculated partial eta squared (η 2 ) to report effect sizes. Results The study cohort showed significant, sustained improvements in both tics and OCD symptoms. At one-year follow-up, Total Tic Severity Scale scores on the YGTSS decreased by 73.3% ( n = 10; mean difference, −11.0; 95% CI, −13.99 to −8.04; p = 0.0025; η 2 = 0.715) compared with the baseline. In parallel, Y-BOCS scores decreased by 85.1% ( n = 10; mean difference, −13.10; 95% CI, −17.71 to −8.49; p = 0.0004; η 2 = 0.639). No adverse effects were reported during this one-year study. Conclusion Pharmacologic modulation of striosomal D 1 R signaling could provide significant, durable benefits for patients with T-OCD. Given its efficacy and safety in reducing both tic and OC symptoms in T-OCD, striosomes may serve as a promising therapeutic target for ICSDs. These findings warrant further investigation through larger, randomized, and placebo-controlled clinical trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Human Neuroscience
Published
2026-11-19
DOI
https://doi.org/10.3389/fnhum.2026.2018962
Primary Topic
Obsessive-Compulsive Spectrum Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Response of tic and obsessive-compulsive symptoms to striosomal dopaminergic modulation in tic-related OCD: an open-label pilot study

Hideki Shimazu, Shinichi Matsumoto, Satoshi Goto
Frontiers in Human Neuroscience
Obsessive-Compulsive Spectrum Disorders
article

Response of tic and obsessive-compulsive symptoms to striosomal dopaminergic modulation in tic-related OCD: an open-label pilot study

Hideki Shimazu, Shinichi Matsumoto, Satoshi Goto
article en

Abstract

Objectives This study investigated the therapeutic potential of striosomes in addressing ICSDs, focusing on the treatment response of tic and obsessive-compulsive (OC) symptoms in tic-related OCD (T-OCD) to a pharmacological intervention designed to enhance striosomal dopamine signaling through D1-type receptors (D1Rs). Methods Ten participants with T-OCD [30% male; mean age, 40.5 years (SD 20.1); mean age at onset, 9.2 years (SD 4.1)] received L-DOPA/carbidopa (50 mg) plus chlorpromazine-phenolphthalinate (5 mg), with doses increased stepwise to three times daily over 8 weeks, then maintained for 1 year. We used the Yale Global Tic Severity Scale (YGTSS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) for clinical assessments. For statistical analyses, we used repeated-measures ANOVA with Dunnett’s post hoc tests and calculated partial eta squared (η 2 ) to report effect sizes. Results The study cohort showed significant, sustained improvements in both tics and OCD symptoms. At one-year follow-up, Total Tic Severity Scale scores on the YGTSS decreased by 73.3% ( n = 10; mean difference, −11.0; 95% CI, −13.99 to −8.04; p = 0.0025; η 2 = 0.715) compared with the baseline. In parallel, Y-BOCS scores decreased by 85.1% ( n = 10; mean difference, −13.10; 95% CI, −17.71 to −8.49; p = 0.0004; η 2 = 0.639). No adverse effects were reported during this one-year study. Conclusion Pharmacologic modulation of striosomal D 1 R signaling could provide significant, durable benefits for patients with T-OCD. Given its efficacy and safety in reducing both tic and OC symptoms in T-OCD, striosomes may serve as a promising therapeutic target for ICSDs. These findings warrant further investigation through larger, randomized, and placebo-controlled clinical trials.

Frontiers in Human NeuroscienceVol. 20
Mukogawa Women's University (JP), Osaka Neurological Institute (JP), Tokushima University (JP)
Obsessive-Compulsive Spectrum Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon